AACR 2023 | Combination therapies with vemurafenib in BRAF v600E–mutant cancers

Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from the VEM-PLUS study, which assessed the efficacy of combination therapies involving vemurafenib in patients with BRAF v600E–mutant cancers. Various trials investigating vemurafenib with sorafenib, crizotinib, or paclitaxel and carboplatin were analyzed, and no increase in overall survival was reported in patients receiving combination therapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.